Literature DB >> 8180951

Butyrate as a differentiating agent: pharmacokinetics, analogues and current status.

H L Newmark1, J R Lupton, C W Young.   

Abstract

The field of butyrate-induced differentiation of neoplastic and non-neoplastic cells is reviewed and possible clinical correlations considered with regard to butyrate, butyrate prodrugs and butyrate analogues. These topics are discussed from the point of view of the concentrations required in vitro for biologic effect, and likely pharmacokinetic behavior in vivo.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8180951     DOI： 10.1016/0304-3835(94)90023-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  25 in total

1.  Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription.

Authors:  Hong-Bo Wang; Peng-Yuan Wang; Xin Wang; Yuan-Lian Wan; Yu-Cun Liu
Journal:  Dig Dis Sci       Date:  2012-06-09       Impact factor: 3.199

2.  Streptanoate, a new anticancer butanoate from Streptomyces sp. DC3.

Authors:  Saisattha Noomnual; Nopporn Thasana; Pareenart Sungkeeree; Skorn Mongkolsuk; Suvit Loprasert
Journal:  J Antibiot (Tokyo)       Date:  2015-09-16       Impact factor: 2.649

3.  Inhibition of human lymphocyte function by organic solvents.

Authors:  A S Shoker; M A Murabit; F F Georges; L F Qualtiere; H G Deneer; K Prasad
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

4.  In vitro intestinal bioaccessibility of alkylglycerols versus triacylglycerols as vehicles of butyric acid.

Authors:  Diana Martín; María I Morán-Valero; Francisco J Señoráns; Guillermo Reglero; Carlos F Torres
Journal:  Lipids       Date:  2011-01-12       Impact factor: 1.880

5.  Identification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex.

Authors:  Leila Alland; Gregory David; Hong Shen-Li; Jason Potes; Rebecca Muhle; Hye-Chun Lee; Harry Hou; Ken Chen; Ronald A DePinho
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

6.  Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.

Authors:  Yanning Ma; Yongfang Yue; Min Pan; Jie Sun; Jue Chu; Xiaoying Lin; Wenxia Xu; Lifeng Feng; Yan Chen; Dingwei Chen; Vivian Y Shin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 7.  Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?

Authors:  Megan W Bourassa; Ishraq Alim; Scott J Bultman; Rajiv R Ratan
Journal:  Neurosci Lett       Date:  2016-02-08       Impact factor: 3.046

8.  n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids.

Authors:  G A Böhmig; P M Krieger; M D Säemann; C Wenhardt; E Pohanka; G J Zlabinger
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

9.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

10.  Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.

Authors:  Xiaodan Su; Liwen Zhang; David M Lucas; Melanie E Davis; Amy R Knapp; Kari B Green-Church; Guido Marcucci; Mark R Parthun; John C Byrd; Michael A Freitas
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.